<DOC>
	<DOCNO>NCT01767675</DOCNO>
	<brief_summary>The purpose study see investigator improve treatment type cancer . They want find effect , good and/or bad , give heat chemotherapy belly , know hyperthermic intraperitoneal chemotherapy ( HIPEC ) , patient type cancer . The goal HIPEC expose cancer leave abdomen surgery high dos chemotherapy . The chemotherapy heat hope make easy get kill cancer cell . The drug use HIPEC carboplatin , Food Drug Administration ( FDA ) approve drug use ovarian , fallopian tube primary peritoneal cancer .</brief_summary>
	<brief_title>Outcomes After Secondary Cytoreductive Surgery With Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy ( HIPEC ) Followed Systemic Combination Chemotherapy Recurrent Platinum-Sensitive Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age ≥ 21 year old . Patients histologic diagnosis epithelial ovarian carcinoma , primary peritoneal carcinoma , fallopian tube carcinoma recur &gt; 6 month since platinumbased chemotherapy ( first recurrence ) schedule secondary surgical evaluation/cytoreduction . Histologic epithelial cell type include serous , endometrioid , clear cell , undifferentiated carcinoma , transitional cell carcinoma , mixed epithelial carcinoma , malignant Brenner 's tumor , adenocarcinoma N.O.S . Karnofsky Performance Status ( KPS ) ≥ 70 % . Diseasefree interval ≤ 30 month . No prior chemotherapy recurrent setting . Prior hormonal therapy permit . Concomitant antineoplastic antihormonal therapy ( include tamoxifen , aromatase inhibitor etc . ) allow patient participate study treatment . Lowdose ( physiologic ) estrogen hormonereplacement therapy ( HRT ) may give . Patients receive maintenance biologic therapy eligible , provide recurrence document 6 month completion primary cytotoxic chemotherapy ( include maintenance chemotherapy ) minimum 3 week elapse since last infusion biologic therapy start protocol intervention , day 1 . Patients consent prior surgical evaluation/cytoreductive surgery . Patients must less equal 0.5 cm residual disease completion secondary surgery eligible study . Patients must , evaluation investigator , appropriate candidate administration 5 6 cycle standard platinumbased combination chemotherapy ( carboplatin paclitaxel , carboplatin liposomal doxorubicin , carboplatin gemcitabine ) follow CRS without HIPEC . Bone marrow function : Hemoglobin ≥ 8.5 g/dL . Absolute neutrophil count ( ANC ) ≥ 1,000/mm3 . Platelets ≥ 100,000/mm3 . Renal function : Creatinine ≤ 1.5mg/dl Hepatic function : Bilirubin ≤ 1.5 time ULN . ALT ≤ 3 time ULN . AST ≤ 3 time ULN . Neurologic function : Peripheral neuropathy ≤ CTC AE grade 2 . Blood coagulation parameter : PT INR ≤ 1.5 PTT ≤ 1.5 time ULN . For patient fulldose oral anticoagulation ( warfarin rivaroxaban ) , inrange INR ( usually 2 3 ) PTT &lt; 1.2 time ULN . Patients childbearing potential must negative serum pregnancy test within 2 week prior CRS must practice effective form contraception study period . Tumors low malignant potential ( borderline carcinoma ) . Subjects receive prior radiotherapy portion abdominal cavity pelvis exclude . Patients history primary endometrial cancer exclude unless follow condition meet : Stage great IA . Not poorly differentiate subtype ( include papillary serous , clear cell FIGO grade 3 lesion ) With exception nonmelanoma skin cancer specific malignancy note , subject invasive malignancy , evidence cancer present within last 1 year whose previous cancer treatment contraindicate protocol therapy , exclude . Subjects know active acute hepatitis . Subjects active infection require parenteral antibiotic . Active coronary artery disease ( define unstable angina positive cardiac stress test ) . Patients history coronary artery disease may include normal stress test within 30 day enrollment . Uncontrolled hypertension define &gt; 140/90 clear surgery time consent.. New York Heart Association ( NYHA ) Class II higher Congestive heart failure . History cerebrovascular disease . Immune deficiency : Clinically significant primary acquire immune deficiency ( i.e . AIDS immunosuppressive medication organ transplant ) . Patients concurrent severe medical problem unrelated malignancy would significantly limit full compliance study place unacceptable risk participation study . Patients know carboplatin cisplatin allergy . Evidence extensive intraperitoneal adhesion time surgery , determine operating surgeon prohibit intraperitoneal therapy . Life expectancy &lt; 12 week .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Secondary Cytoreductive Surgery</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Hyperthermic Intraperitoneal Chemotherapy ( HIPEC )</keyword>
	<keyword>12-275</keyword>
</DOC>